Long-term treatment with suberythropoietic Epo is vaso- and neuroprotective in experimental diabetic retinopathy.

@article{Wang2011LongtermTW,
  title={Long-term treatment with suberythropoietic Epo is vaso- and neuroprotective in experimental diabetic retinopathy.},
  author={Qian Wang and Stefan Gorbey and Frederick Pfister and Simone Hoeger and Andrea Dorn-Beineke and Katja Kr{\"u}gel and Elena Berrone and Liang Wu and Thomas Korff and Jihong Lin and Stefanie Busch and Andreas Reichenbach and Yuxi Feng and H Hammes},
  journal={Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology},
  year={2011},
  volume={27 6},
  pages={769-82}
}
BACKGROUND/AIMS Diabetic retinopathy is characterized by pericyte loss and vasoregression both in the clinic and in animal models. A mild neurodegeneration with loss of ganglion cells is also described in the diabetic retina. Like VEGF-A, Epo is angioprotective and, in high doses, neuroprotective, however, without affecting vessel permeability. This study was to investigate the effect of a long-term suberythropoietic dose of Epo on vascular damage and neurodegeneration in a rat model of… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 22 extracted citations

Erythropoietin in diabetic retinopathy

Vision Research • 2017
View 8 Excerpts
Highly Influenced

Efficacy Evaluation of AAV2-EPO to Diabetic Retinopathy Based on Molecular Hyperspectral Imaging System

2015 Seventh International Conference on Measuring Technology and Mechatronics Automation • 2015
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 69 references

Similar Papers

Loading similar papers…